Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Global $5 Billion Anaplastic Lymphoma Kinase ALK Inhibitors Market Opportunities to 2026: Clinical & Commercial Insight of Crizotinib, Certinib, Alectinib, Brigatinib, Lorlatinib
2 The Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market is expected to grow by $ 3.43 billion during
3 Global Anaplastic Lymphoma Kinase ALK Inhibitors Market
4 $ 3.43 Billion growth expected in Anaplastic Lymphoma Kinase (ALK) Inhibitors Market | 20.14% YOY growth in 2021 amid COVID-19 Spread | North America to Notice Maximum Growth | Technavio
5 Anaplastic Lymphoma Kinase Inhibitors Market
6 Global Cancer ALK Inhibitor Market is estimated to be US$ 10.6 billion by 2030 with a
7 2021 Anaplastic Lymphoma Kinase Inhibitors Pipeline Market Report
8 ViziShot 2 FLEX 19 G EBUS-TBNA Needle effective tool in helping guide lung cancer treatment, study says
9 Chronic progression of lung cancer recurrence after surgery | CMAR
10 ALK Non-Small Cell Lung Cancer Markets, Forecast to 2030
11 U.S. FDA Expands Approval of Pfizer's LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
12 Pfizer gets sales nod for ALK-positive lung cancer drug
13 Lilly to Present New Data from Oncology Portfolio at ESMO Congress
14 Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma
15 Bazhenova Compares Frontline ALK Inhibitors for ALK+ NSCLC
16 AstraZeneca : IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
17 FDA Approves Pfizer Med for Rare Form of Pediatric Non-Hodgkin Lymphoma
18 Japanese regulator brings Alunbrig into frontline setting
19 Global Kinase Inhibitors Markets 2019-2020 & 2027
20 Takeda expects expanded insurance benefits for lung cancer drug in H1
21 Korean biotech firms hire foreign scientific advisors for global commercialization
22 FoundationOne®CDx Receives FDA-Approval as a Companion Diagnostic for ALUNBRIG® (brigatinib) to Identify Patients with ALK positive Metastatic Non-Small Cell Lung Cancer
23 Clinical Utility of ALK Fusion Detection by Liquid Biopsy
24 Systematic review of sequencing of ALK inhibitors in ALK-positive non- | LCTT
25 Oral Chemotherapy Market banking on Regulatory Approvals of New Drug Candidates
26 Pfizer's XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
27 Compounding Chemotherapy Market to Reach USD 635.58 Million
28 European Commission Approves Takeda's ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC
29 Health Canada approves new indication for lung cancer treatment option ALUNBRIG®
30 Foundationone CDx gets FDA nod for lung cancer drug
31 Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with
32 'Alecensa beat crizotinib as treatment of ALK-positive NSCLC'
33 New cancer drugs lead to life-threatening financial choices
34 Roche's Tecentriq gets fourth European NSCLC indication
35 Takeda's Alunbrig available as primary therapy for lung cancer
36 Immunotherapy for Metastatic Non‐Small Cell Lung Cancer: Real‐World Data from an Academic Central and Eastern European Center
37 The Lancet Respiratory Medicine Published Study Shows Ensartinib Holds Promise as a New Treatment Option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)
38 Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib
39 Global Natural Killer Cell Therapies Competitive Landscape, Technology, and Pipeline Analysis | DelveInsight
40 Brigatinib for ALK-positive metastatic non-small-cell lung cancer: des | DDDT
41 Delivering innovation: 2020 oncology market outlook
42 LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer | Small Molecules | News Channels
43 Hodgkin's Lymphoma Drugs Market – Advances in Diagnostic Methods to Boost Growth through 2019-2023 | Technavio
44 Crizotinib in a patient with pulmonary adenocarcinoma | OTT
45 Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC
46 Pfizer's lung cancer drug Xalkori threatened by new rivals
47 New Breakthrough Treatment for Patients with ALK-Positive Lung Cancer
48 Merck's Keytruda dominates space despite Roche's Tecentriq approval
49 ALK Positive Lung Cancer Treatment Market 2018-2026 Shows Industry Size, Consumption, Suppliers, Market Dynamics, Types, Applications, and Regions | Coherent Market Insights
50 Plasma Cell‐Free DNA Genotyping: From an Emerging Concept to a Standard‐of‐Care Tool in Metastatic Non‐Small Cell Lung Cancer
51 FDA Accepts Supplemental New Drug Application for Pfizer's XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma
52 TESARO Enters into Exclusive License Agreement with Amgen to Acquire Rights to Anaplastic Lymphoma Kinase (ALK) Program
53 FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
54 FDA gives thumbs up to Takeda's lung cancer drug
55 Lung cancer 2nd treatment Alunbrig likely to get insurance coverage
56 PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
57 Accelerated FDA approval for Alunbrig in first-line setting for rare a
58 Newcastle scientists make 'major breakthrough' in childhood cancer treatment
59 Zykadia (Ceritinib; Novartis) Drug Report 2017-2026
60 FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer
61 Pfizer's lorlatinib got compassionate use the most in 2020
62 Non-Small Cell Lung Cancer Market Size Incredible Possibilities And Growth Analysis And Forecast To 2026 | Pfi
63 The TKI Lung Cancer Market in China
64 Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda's Late-Stage Lung Cancer Portfolio
65 Pfizer 2020: Cancer and COVID-19 – PharmaLive
66 Patent Medicine Market Report 2020, Industry Size, Growth, Regional Analysis, Current Market Trends, Opportunities, Top Drug Development Companies, Statistics, Growing Demand for Patent Medicine in North America
67 Global Roundup, March 5 | BioSpace
68 Stated preferences in non-small cell lung cancer | PPA
69 PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS
70 Checkpoint Therapeutics Announces Presentation of Updated
71 Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
72 European Commission Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
73 Roche working to identify treatment options for lung cancer patients
74 Takeda 2020: The incredible growing/shrinking pharma – PharmaLive
75 Roche launches first in vitro diagnostic IHC test to detect ROS1 protein in cancers
76 Takeda Announces FDA Accelerated Approval of ALUNBRIGTM (brigatinib)
77 PFIZER REPORTS THIRD-QUARTER 2020 RESULTS
78 Novartis Reports Positive Trial Results For LDK378 In ALK+ NSCLC
79 Takeda gets return on Ariad buy with approval of brigatinib
80 New Genetic Variant Discovered to Cause Peritoneal Mesothelioma
81 Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
82 Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
83 Chugai's ALK Inhibitor "Alectinib," New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United States
84 Rozlytrek (entrectinib) for the Treatment of Solid Tumours, Japan
85 NICE final guidance backs Pfizer's Lorviqua
86 Form 10-K Lantern Pharma Inc. For: Dec 31
87 Takeda gets positive CHMP opinion for ALUNBRIG
88 Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline
89 Roche 2020: Built for innovation – PharmaLive
90 New approvals and indication from FDA: Alunbrig, VESIcare LC, Kynmobi and more
91 U.S. Food And Drug Administration Approves Pfizer's XALKORI® (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
92 New Alecensa approval adds to lung cancer competition
93 Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
94 KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced...
95 Xcovery Raises $20M through Equity Investment from China's Betta Pharmaceuticals for Development of ALK Inhibitor
96 Japan first to approve Roche's lung cancer drug alectinib
97 The precision medicine approach to cancer therapy: part 1 — solid tumours
98 5 Highlights in Pharmacy This Week
99 IDEAYA Bio: New GSK Partnership, $3B In Potential Cash Milestones, And 2 Key Therapeutics Advancing Rapidly, 34% Upside
100 ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More